Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: PuddleGlum who wrote (1113)	8/17/1999 1:36:00 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 1686

PuddleGlum, I didn't think I was being harsh. His position on the stock really doesn't matter to me. I do object to lack of substance compounded by characterization. Whether it is "I expect Biogen to settle with Berlex," or "Biogen only has one drug," or "Biogen is going to kick ass," or "Biogen has the best pipeline in the whole world." All statements lack substance and put negative or positive aspect on the company. If you said, "Biogen has: revenues powered primarily by growing Avonex sales; growing royalties powered primarily by Intron A sales; a maturing pipeline that includes potential treatments for psoraiasis, asthma, lupus, ITP, arthritis, cancer, diabetes, and congestive heart failure; an ongoing research program that continues to generate INDs; and a strong balance sheet with over $600MM cash." Then I would say you had characterized the company and backed it up with substance. Or if you said, "Biogen faces a real court battle with Berlex over ongoing patent issues...[because of ___ ]" then that would also be a substantial comment. Again, not meaning to be harsh to PMF, just trying to shine some light on his statements and force PMF to back up characterizations with fact.